The world's scientific and social network for malaria professionals
Subscribe to free Newsletter | 10087 malaria professionals are enjoying the free benefits of MalariaWorld today

vaccine

Open Access | Quantitative PCR Evaluation of Cellular Immune Responses in Kenyan Children Vaccinated with a Candidate Malaria Vaccine

December 24, 2009 - 12:55 -- Ingeborg van Schayk
Tags: 
Author(s): 
Jedidah Mwacharo, Susanna J. Dunachie, Oscar Kai, Adrian V. S. Hill, Philip Bejon, Helen A. Fletcher
Reference: 
PLoS ONE 4(12): e8434

Quantitative PCR is a useful method for evaluating vaccine induced cell mediated immune responses in frozen PBMC from children in a malaria endemic country.

Person: 
Country: 

Evaluation of the safety and immunogenicity of Plasmodium falciparum apical membrane antigen 1, merozoite surface protein 1 or RTS, S vaccines with adjuvant system AS02A administered alone or concurrently in rhesus monkeys

December 5, 2009 - 16:19 -- Kabogo Ndegwa
Author(s): 
S. Pichyangkul, P. Tongtawe, U. Kum-Arb, K. Yongvanitchit, M. Gettayacamin, M.R. Hollingdale, A. Limsalakpetch, V.A. Stewart, D.E. Lanar, S. Dutta, E. Angov, L.A Ware, E.S. Bergmann-Leitner, B. House, G. Voss, M.C. Dubois, J.D. Cohen, M.M. Fukuda, D.G. Heppner, R.S. Miller.
Reference: 
Vaccine, Volume 28, Issue 2, 11 December 2009, Pages 452-462, doi:10.1016/j.vaccine.2009.10.022

In an effort to broaden the immune response induced by the RTS,S/AS02A,vaccine, we have evaluated the immunogenicity of the RTS,S antigen when combined with MSP142 and with AMA1, antigens derived from the asexual blood stage.

Technology: 
Medical Condition: 

The Synthetic Plasmodium falciparum Circumsporozoite Peptide PfCS102 as a Malaria Vaccine Candidate: A Randomized Controlled Phase I Trial

November 10, 2009 - 13:53 -- Ingeborg van Schayk
Tags: 
Author(s): 
Audran R, Lurati-Ruiz F, Genton B, Blythman HE, Ofori-Anyinam O, et al.
Reference: 
PLoS ONE 4(10): e7304

PfCS102 peptide was safe and highly immunogenic, allowing the design of more advanced trials to test its potential for protection. Two or three immunizations with a dose of 30 µg formulated with AS02A appeared the most appropriate choice for such studies.

Technology: 
Medical Condition: 

Randomized Controlled Trial of RTS,S/AS02D and RTS,S/AS01E Malaria Candidate Vaccines Given According to Different Schedules in Ghanaian Children

November 10, 2009 - 13:46 -- Ingeborg van Schayk
Tags: 
Author(s): 
Owusu-Agyei S, Ansong D, Asante K, Kwarteng Owusu S, Owusu R, et al.
Reference: 
PLoS ONE 4(10): e7302

Both candidate malaria vaccines were well tolerated. Anti-circumsporozoite responses were greater with RTS,S/AS01E than RTS,S/AS02D and when 3 rather than 2 doses were given. This study supports the selection of RTS,S/AS01E and a 3 dose schedule for further development in children and infants.

Technology: 
Country: 

Special Focus Review: The role of Plasmodium falciparum variant surface antigens in protective immunity and vaccine development

October 25, 2009 - 16:06 -- Ingeborg van Schayk
Author(s): 
Lars Hviid
Reference: 
Human Vaccines, Volume 6, Issue 1, January 2010

This review summarizes the evidence that VSAs are important targets of NAI, discusses why VSA-based vaccines might be feasible despite the extensive intra- and interclonal variation of VSAs, and how vaccines based on this type of antigens fit into the current global strategy to reduce, eliminate, and eventually eradicate the burden of malaria.

Technology: 
Medical Condition: 
Medical Treatment: 
Subscribe to RSS - vaccine